154 related articles for article (PubMed ID: 27329591)
1. PiwiRNA-651 as marker of treatment response and survival in classical Hodgkin lymphoma.
Cordeiro A; Navarro A; Gaya A; Díaz-Beyá M; Gonzalez-Farré B; Castellano JJ; Fuster D; Martínez C; Martínez A; Monzó M
Oncotarget; 2016 Jul; 7(29):46002-46013. PubMed ID: 27329591
[TBL] [Abstract][Full Text] [Related]
2. Suppressor of cytokine signaling 1 gene mutation status as a prognostic biomarker in classical Hodgkin lymphoma.
Lennerz JK; Hoffmann K; Bubolz AM; Lessel D; Welke C; Rüther N; Viardot A; Möller P
Oncotarget; 2015 Oct; 6(30):29097-110. PubMed ID: 26336985
[TBL] [Abstract][Full Text] [Related]
3. Classical Hodgkin lymphoma, lymphocyte depleted type: clinicopathological analysis and prognostic comparison with other types of classical Hodgkin lymphoma.
Karube K; Niino D; Kimura Y; Ohshima K
Pathol Res Pract; 2013 Apr; 209(4):201-7. PubMed ID: 23478005
[TBL] [Abstract][Full Text] [Related]
4. Expression Levels of PIWI-interacting RNA, piR-823, Are Deregulated in Tumor Tissue, Blood Serum and Urine of Patients with Renal Cell Carcinoma.
Iliev R; Fedorko M; Machackova T; Mlcochova H; Svoboda M; Pacik D; Dolezel J; Stanik M; Slaby O
Anticancer Res; 2016 Dec; 36(12):6419-6423. PubMed ID: 27919963
[TBL] [Abstract][Full Text] [Related]
5. Non-Coding RNAs in Hodgkin Lymphoma.
Cordeiro A; Monzó M; Navarro A
Int J Mol Sci; 2017 May; 18(6):. PubMed ID: 28555062
[TBL] [Abstract][Full Text] [Related]
6. Rare occurrence of biallelic CYLD gene mutations in classical Hodgkin lymphoma.
Schmidt A; Schmitz R; Giefing M; Martin-Subero JI; Gesk S; Vater I; Massow A; Maggio E; Schneider M; Hansmann ML; Siebert R; Küppers R
Genes Chromosomes Cancer; 2010 Sep; 49(9):803-9. PubMed ID: 20607853
[TBL] [Abstract][Full Text] [Related]
7. Small and big Hodgkin-Reed-Sternberg cells of Hodgkin lymphoma cell lines L-428 and L-1236 lack consistent differences in gene expression profiles and are capable to reconstitute each other.
Rengstl B; Kim S; Döring C; Weiser C; Bein J; Bankov K; Herling M; Newrzela S; Hansmann ML; Hartmann S
PLoS One; 2017; 12(5):e0177378. PubMed ID: 28505189
[TBL] [Abstract][Full Text] [Related]
8. Characteristics and outcomes of patients with nodular lymphocyte-predominant Hodgkin lymphoma versus those with classical Hodgkin lymphoma: a population-based analysis.
Gerber NK; Atoria CL; Elkin EB; Yahalom J
Int J Radiat Oncol Biol Phys; 2015 May; 92(1):76-83. PubMed ID: 25863756
[TBL] [Abstract][Full Text] [Related]
9. Role of vascular endothelial growth factor C in classical Hodgkin lymphoma.
Rueda A; Olmos D; Vicioso L; Quero C; Gallego E; Pajares-Hachero BI; Mendiola M; Casanova M; Álvarez M; Provencio M; Alba E
Leuk Lymphoma; 2015 May; 56(5):1286-94. PubMed ID: 25098430
[TBL] [Abstract][Full Text] [Related]
10. Cellular Senescence Markers p16INK4a and p21CIP1/WAF Are Predictors of Hodgkin Lymphoma Outcome.
Caliò A; Zamò A; Ponzoni M; Zanolin ME; Ferreri AJ; Pedron S; Montagna L; Parolini C; Fraifeld VE; Wolfson M; Yanai H; Pizzolo G; Doglioni C; Vinante F; Chilosi M
Clin Cancer Res; 2015 Nov; 21(22):5164-72. PubMed ID: 26199387
[TBL] [Abstract][Full Text] [Related]
11. Micro-RNA (miRNA) profile in Hodgkin lymphoma: association between clinical and pathological variables.
Paydas S; Acikalin A; Ergin M; Celik H; Yavuz B; Tanriverdi K
Med Oncol; 2016 Apr; 33(4):34. PubMed ID: 26951445
[TBL] [Abstract][Full Text] [Related]
12. The favorable role of homozygosity for killer immunoglobulin-like receptor (KIR) A haplotype in patients with advanced-stage classic Hodgkin lymphoma.
La Nasa G; Greco M; Littera R; Oppi S; Celeghini I; Caria R; Lai S; Porcella R; Martino M; Romano A; Di Raimondo F; Gallamini A; Carcassi C; Caocci G
J Hematol Oncol; 2016 Mar; 9():26. PubMed ID: 26983546
[TBL] [Abstract][Full Text] [Related]
13. Serum CD163 and TARC as disease response biomarkers in classical Hodgkin lymphoma.
Jones K; Vari F; Keane C; Crooks P; Nourse JP; Seymour LA; Gottlieb D; Ritchie D; Gill D; Gandhi MK
Clin Cancer Res; 2013 Feb; 19(3):731-42. PubMed ID: 23224400
[TBL] [Abstract][Full Text] [Related]
14. Grey zone lymphoma with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma: a clinicopathological study of 14 Epstein-Barr virus-positive cases.
Elsayed AA; Satou A; Eladl AE; Kato S; Nakamura S; Asano N
Histopathology; 2017 Mar; 70(4):579-594. PubMed ID: 27735994
[TBL] [Abstract][Full Text] [Related]
15. Insulin-like growth factor-1 receptor is associated with better prognosis in classical Hodgkin's lymphoma: Correlation with MET expression.
Koh YW; Yoon DH; Suh C; Cha HJ; Huh J
Int J Exp Pathol; 2015 Aug; 96(4):232-9. PubMed ID: 25916750
[TBL] [Abstract][Full Text] [Related]
16. Global long terminal repeat activation participates in establishing the unique gene expression programme of classical Hodgkin lymphoma.
Edginton-White B; Cauchy P; Assi SA; Hartmann S; Riggs AG; Mathas S; Cockerill PN; Bonifer C
Leukemia; 2019 Jun; 33(6):1463-1474. PubMed ID: 30546079
[TBL] [Abstract][Full Text] [Related]
17. Comparison of miRNA profiles of microdissected Hodgkin/Reed-Sternberg cells and Hodgkin cell lines versus CD77+ B-cells reveals a distinct subset of differentially expressed miRNAs.
Van Vlierberghe P; De Weer A; Mestdagh P; Feys T; De Preter K; De Paepe P; Lambein K; Vandesompele J; Van Roy N; Verhasselt B; Poppe B; Speleman F
Br J Haematol; 2009 Dec; 147(5):686-90. PubMed ID: 19775296
[TBL] [Abstract][Full Text] [Related]
18. Plasma microRNA are disease response biomarkers in classical Hodgkin lymphoma.
Jones K; Nourse JP; Keane C; Bhatnagar A; Gandhi MK
Clin Cancer Res; 2014 Jan; 20(1):253-64. PubMed ID: 24222179
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of COX-2 expression and correlation with Bcl-2 and VEGF expression, microvessel density, and clinical variables in classical Hodgkin lymphoma.
Koh YW; Park C; Yoon DH; Suh C; Huh J
Am J Surg Pathol; 2013 Aug; 37(8):1242-51. PubMed ID: 23851330
[TBL] [Abstract][Full Text] [Related]
20. STAT6 and STAT1 are essential antagonistic regulators of cell survival in classical Hodgkin lymphoma cell line.
Baus D; Nonnenmacher F; Jankowski S; Döring C; Bräutigam C; Frank M; Hansmann ML; Pfitzner E
Leukemia; 2009 Oct; 23(10):1885-93. PubMed ID: 19440213
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
